Clinical significance of CD8<sup>+</sup> and FoxP3<sup>+</sup> tumor‑infiltrating lymphocytes and MFG‑E8 expression in lower rectal cancer with preoperative chemoradiotherapy

Harada,Yuzo; Kazama,Shinsuke; Morikawa,Teppei; Sonoda,Hirofumi; Ishi,Hiroaki; Emoto,Shigenobu; Murono,Koji; Kaneko,Manabu; Sasaki,Kazuhito; Shuno,Yasutaka; Nishikawa,Takeshi; Tanaka,Toshiaki; Kawai,Kazushige; Hata,Keisuke; Nozawa,Hiroaki; Ushiku,Tetsuo; Tahara,Hideaki; Ishihara,Soichiro

doi:10.3892/mco.2021.2249

May-2021 Volume 14 Issue 5

Full Size Image

Journals

International Journal of Molecular Medicine

International Journal of Molecular Medicine is an international journal devoted to molecular mechanisms of human disease.

International Journal of Oncology

International Journal of Oncology is an international journal devoted to oncology research and cancer treatment.

Molecular Medicine Reports

Covers molecular medicine topics such as pharmacology, pathology, genetics, neuroscience, infectious diseases, molecular cardiology, and molecular surgery.

Oncology Reports

Oncology Reports is an international journal devoted to fundamental and applied research in Oncology.

Experimental and Therapeutic Medicine

Experimental and Therapeutic Medicine is an international journal devoted to laboratory and clinical medicine.

Oncology Letters

Oncology Letters is an international journal devoted to Experimental and Clinical Oncology.

Biomedical Reports

Explores a wide range of biological and medical fields, including pharmacology, genetics, microbiology, neuroscience, and molecular cardiology.

Molecular and Clinical Oncology

International journal addressing all aspects of oncology research, from tumorigenesis and oncogenes to chemotherapy and metastasis.

World Academy of Sciences Journal

Multidisciplinary open-access journal spanning biochemistry, genetics, neuroscience, environmental health, and synthetic biology.

International Journal of Functional Nutrition

Open-access journal combining biochemistry, pharmacology, immunology, and genetics to advance health through functional nutrition.

International Journal of Epigenetics

Publishes open-access research on using epigenetics to advance understanding and treatment of human disease.

Medicine International

An International Open Access Journal Devoted to General Medicine.

May-2021 Volume 14 Issue 5

Full Size Image

Article

Clinical significance of CD8⁺ and FoxP3⁺ tumor‑infiltrating lymphocytes and MFG‑E8 expression in lower rectal cancer with preoperative chemoradiotherapy

Authors:
- Yuzo Harada
- Shinsuke Kazama
- Teppei Morikawa
- Hirofumi Sonoda
- Hiroaki Ishi
- Shigenobu Emoto
- Koji Murono
- Manabu Kaneko
- Kazuhito Sasaki
- Yasutaka Shuno
- Takeshi Nishikawa
- Toshiaki Tanaka
- Kazushige Kawai
- Keisuke Hata
- Hiroaki Nozawa
- Tetsuo Ushiku
- Hideaki Tahara
- Soichiro Ishihara
View Affiliations / Copyright

Affiliations: Division of Surgical Oncology, Department of Surgery, Faculty of Medicine, The University of Tokyo, Tokyo 113‑8655, Japan, Department of Pathology, NTT Medical Center Tokyo, Tokyo 141‑8625, Japan, Department of Pathology, The University of Tokyo, Tokyo 113‑8655, Japan, Project Division of Cancer Biomolecular Therapy, Institute of Medical Science, The University of Tokyo, Tokyo 108‑8639, Japan
Article Number: 87
|
Published online on: March 5, 2021

https://doi.org/10.3892/mco.2021.2249
Expand metrics +

Abstract

Preoperative chemoradiotherapy (CRT) for rectal cancer contributes to tumor down‑staging and decreases locoregional recurrence. However, each patient shows a significantly different response to CRT. Therefore, the identification of predictive factors to CRT response would be beneficial to avoid unnecessary treatment. Cancer immunity in patients has been suggested to play an important role in the eradication of the tumor by CRT. In the present study, the utility of CD8+ and forkhead box P3 (FoxP3)⁺ tumor‑infiltrating lymphocytes (TILs) and the expression of a novel immuno‑regulatory factor, lactadherin (MFG‑E8), in predicting CRT effectiveness in patients with rectal cancer was examined. A total of 61 patients with rectal cancer, who underwent curative resection following CRT were included in the study. The numbers of CD8⁺ and FoxP3⁺ TILs in a biopsy taken before CRT and MFG‑E8 expression level in the specimens obtained at the time of the surgery after CRT were examined using immunohistochemical staining, and their association with clinicopathological characteristics, including patient survival, was determined. The tumors with more CD8⁺ TILs in the biopsy samples before CRT showed a significantly more favorable CRT response. The patients with tumors and a higher number of CD8⁺ TILs before CRT also exhibited significantly longer disease‑free and overall survival times. Higher MFG‑E8 expression level in post‑CRT specimens was significantly associated with favorable CRT response; however, no significant association was found with any other clinicopathological characteristics, including survival time. The number of CD8⁺ TILs before CRT was a valuable predictor for CRT response and was associated with favorable prognosis in patients with lower rectal cancer and who were treated with CRT. High MFG‑E8 expression level after CRT was also associated with a favorable CRT response.

View Figures

View References

1	Folkesson J, Birgisson H, Pahlman L, Cedermark B, Glimelius B and Gunnarsson U: Swedish rectal cancer trial: Long lasting benefits from radiotherapy on survival and local recurrence rate. J Clin Oncol. 23:5644–5650. 2005.PubMed/NCBI View Article : Google Scholar
2	Peeters KC, Marijnen CA, Nagtegaal ID, Kranenbarg EK, Putter H, Wiggers T, Rutten H, Pahlman L, Glimelius B, Leer JW, et al: The TME trial after a median follow-up of 6 years: Increased local control but no survival benefit in irradiated patients with resectable rectal carcinoma. Ann Surg. 246:693–701. 2007.PubMed/NCBI View Article : Google Scholar
3	Bosset JF, Collette L, Calais G, Mineur L, Maingon P, Radosevic-Jelic L, Daban A, Bardet E, Beny A and Ollier JC: EORTC Radiotherapy Group Trial 22921. Chemotherapy with preoperative radiotherapy in rectal cancer. N Engl J Med. 355:1114–1123. 2006.PubMed/NCBI View Article : Google Scholar
4	Topova L, Hellmich G, Puffer E, Schubert C, Christen N, Boldt T, Wiedemann B, Witzigmann H and Stelzner S: Prognostic value of tumor response to neoadjuvant therapy in rectal carcinoma. Dis Colon Rectum. 54:401–411. 2011.PubMed/NCBI View Article : Google Scholar
5	Tomono A, Yamashita K, Kanemitsu K, Sumi Y, Yamamoto M, Kanaji S, Imanishi T, Nakamura T, Suzuki S, Tanaka K and Kakeji Y: Prognostic significance of pathological response to preoperative chemoradiotherapy in patients with locally advanced rectal cancer. Int J Clin Oncol. 21:344–349. 2016.PubMed/NCBI View Article : Google Scholar
6	Tada N, Kawai K, Tsuno NH, Ishihara S, Yamaguchi H, Sunami E, Kitayama J, Oba K and Watanabe T: Prediction of the preoperative chemoradiotherapy response for rectal cancer by peripheral blood lymphocyte subsets. World J Surg Oncol. 13(30)2015.PubMed/NCBI View Article : Google Scholar
7	Ishihara S, Iinuma H, Fukushima Y, Akahane T, Horiuchi A, Shimada R, Shibuya H, Hayama T, Yamada H, Nozawa K, et al: Radiation-induced apoptosis of peripheral blood lymphocytes is correlated with histological regression of rectal cancer in response to preoperative chemoradiotherapy. Ann Surg Oncol. 19:1192–1198. 2012.PubMed/NCBI View Article : Google Scholar
8	Shinto E, Hase K, Hashiguchi Y, Sekizawa A, Ueno H, Shikina A, Kajiwara Y, Kobayashi H, Ishiguro M and Yamamoto J: CD8+ and FOXP3+ tumor-infiltrating T cells before and after chemoradiotherapy for rectal cancer. Ann Surg Oncol. 21 (Suppl 3):S414–S421. 2014.PubMed/NCBI View Article : Google Scholar
9	Yasuda K, Nirei T, Sunami E, Nagawa H and Kitayama J: Density of CD4(+) and CD8(+) T lymphocytes in biopsy samples can be a predictor of pathological response to chemoradiotherapy (CRT) for rectal cancer. Radiat Oncol. 6(49)2011.PubMed/NCBI View Article : Google Scholar
10	McCoy MJ, Hemmings C, Miller TJ, Austin SJ, Bulsara MK, Zeps N, Nowak AK, Lake RA and Platell CF: Low stromal Foxp3+ regulatory T-cell density is associated with complete response to neoadjuvant chemoradiotherapy in rectal cancer. Br J Cancer. 113:1677–1686. 2015.PubMed/NCBI View Article : Google Scholar
11	Teng F, Meng X, Kong L, Mu D, Zhu H, Liu S, Zhang J and Yu J: Tumor-infiltrating lymphocytes, forkhead box P3, programmed death ligand-1, and cytotoxic T lymphocyte-associated antigen-4 expressions before and after neoadjuvant chemoradiation in rectal cancer. Transl Res. 166:721–732.e1. 2015.PubMed/NCBI View Article : Google Scholar
12	Anitei MG, Zeitoun G, Mlecnik B, Marliot F, Haicheur N, Todosi AM, Kirilovsky A, Lagorce C, Bindea G, Ferariu D, et al: Prognostic and predictive values of the immunoscore in patients with rectal cancer. Clin Cancer Res. 20:1891–1899. 2014.PubMed/NCBI View Article : Google Scholar
13	Taylor MR, Couto JR, Scallan CD, Ceriani RL and Peterson JA: Lactadherin (formerly BA46), a membrane-associated glycoprotein expressed in human milk and breast carcinomas, promotes Arg-Gly-Asp (RGD)-dependent cell adhesion. DNA Cell Biol. 16:861–869. 1997.PubMed/NCBI View Article : Google Scholar
14	Hanayama R, Tanaka M, Miwa K, Shinohara A, Iwamatsu A and Nagata S: Identification of a factor that links apoptotic cells to phagocytes. Nature. 417:182–187. 2002.PubMed/NCBI View Article : Google Scholar
15	Miyasaka K, Hanayama R, Tanaka M and Nagata S: Expression of milk fat globule epidermal growth factor 8 in immature dendritic cells for engulfment of apoptotic cells. Eur J Immunol. 34:1414–1422. 2004.PubMed/NCBI View Article : Google Scholar
16	Li BZ, Zhang HY, Pan HF and Ye DQ: Identification of MFG-E8 as a novel therapeutic target for diseases. Expert Opin Ther Targets. 17:1275–1285. 2013.PubMed/NCBI View Article : Google Scholar
17	Jinushi M, Nakazaki Y, Dougan M, Carrasco DR, Mihm M and Dranoff G: MFG-E8-mediated uptake of apoptotic cells by APCs links the pro- and antiinflammatory activities of GM-CSF. J Clin Invest. 117:1902–1913. 2007.PubMed/NCBI View Article : Google Scholar
18	Tibaldi L, Leyman S, Nicolas A, Notebaert S, Dewulf M, Ngo TH, Zuany-Amorim C, Amzallag N, Bernard-Pierrot I, Sastre-Garau X and Théry C: New blocking antibodies impede adhesion, migration and survival of ovarian cancer cells, highlighting MFGE8 as a potential therapeutic target of human ovarian carcinoma. PLoS One. 8(e72708)2013.PubMed/NCBI View Article : Google Scholar
19	Sugano G, Bernard-Pierrot I, Laé M, Battail C, Allory Y, Stransky N, Krumeich S, Lepage ML, Maille P, Donnadieu MH, et al: Milk fat globule-epidermal growth factor-factor VIII (MFGE8)/lactadherin promotes bladder tumor development. Oncogene. 30:642–653. 2011.PubMed/NCBI View Article : Google Scholar
20	Soki FN, Koh AJ, Jones JD, Kim YW, Dai J, Keller ET, Pienta KJ, Atabai K, Roca H and McCauley LK: Polarization of prostate cancer-associated macrophages is induced by milk fat globule-EGF factor 8 (MFG-E8)-mediated efferocytosis. J Biol Chem. 289:24560–24572. 2014.PubMed/NCBI View Article : Google Scholar
21	Oba J, Moroi Y, Nakahara T, Abe T, Hagihara A and Furue M: Expression of milk fat globule epidermal growth factor-VIII may be an indicator of poor prognosis in malignant melanoma. Br J Dermatol. 165:506–512. 2011.PubMed/NCBI View Article : Google Scholar
22	Zhao Q, Xu L, Sun X, Zhang K, Shen H, Tian Y, Sun F and Li Y: MFG-E8 overexpression promotes colorectal cancer progression via AKT/MMPs signalling. Tumour Biol. 39(1010428317707881)2017.PubMed/NCBI View Article : Google Scholar
23	Kusunoki R, Ishihara S, Tada Y, Oka A, Sonoyama H, Fukuba N, Oshima N, Moriyama I, Yuki T, Kawashima K, et al: Role of milk fat globule-epidermal growth factor 8 in colonic inflammation and carcinogenesis. J Gastroenterol. 50:862–875. 2015.PubMed/NCBI View Article : Google Scholar
24	Brierley JD, Gospodarowicz MK and Wittekind C (eds): The TNM classification of malignant tumours, 8th edition. Wiley Blackwell, Oxford, 2017.
25	Japanese classification of colorectal carcinoma. Kanehara & Co., Ltd., Tokyo, 2018.
26	Kanemura T, Miyata H, Makino T, Tanaka K, Sugimura K, Hamada-Uematsu M, Mizote Y, Uchida H, Miyazaki Y, Takahashi T, et al: Immunoregulatory influence of abundant MFG-E8 expression by esophageal cancer treated with chemotherapy. Cancer Sci. 109:3393–3402. 2018.PubMed/NCBI View Article : Google Scholar
27	Crane CH, Skibber JM, Feig BW, Vauthey JN, Thames HD, Curley SA, Rodriguez-Bigas MA, Wolff RA, Ellis LM, Delclos ME, et al: Response to preoperative chemoradiation increases the use of sphincter-preserving surgery in patients with locally advanced low rectal carcinoma. Cancer. 97:517–524. 2003.PubMed/NCBI View Article : Google Scholar
28	Habr-Gama A, Perez RO, Proscurshim I, Campos FG, Nadalin W, Kiss D and Gama-Rodrigues J: Patterns of failure and survival for nonoperative treatment of stage c0 distal rectal cancer following neoadjuvant chemoradiation therapy. J Gastrointest Surg. 10:1319–1329. 2006.PubMed/NCBI View Article : Google Scholar
29	Yu CS, Yun HR, Shin EJ, Lee KY, Kim NK, Lim SB, Oh ST, Kang SB, Choi WJ, Lee WY, et al: Local excision after neoadjuvant chemoradiation therapy in advanced rectal cancer: A national multicenter analysis. Am J Surg. 206:482–487. 2013.PubMed/NCBI View Article : Google Scholar
30	McCoy MJ, Hemmings C, Anyaegbu CC, Austin SJ, Lee-Pullen TF, Miller TJ, Bulsara MK, Zeps N, Nowak AK, Lake RA and Platell CF: Tumour-infiltrating regulatory T cell density before neoadjuvant chemoradiotherapy for rectal cancer does not predict treatment response. Oncotarget. 8:19803–19813. 2017.PubMed/NCBI View Article : Google Scholar
31	Jinushi M, Sato M, Kanamoto A, Itoh A, Nagai S, Koyasu S, Dranoff G and Tahara H: Milk fat globule epidermal growth factor-8 blockade triggers tumor destruction through coordinated cell-autonomous and immune-mediated mechanisms. J Exp Med. 206:1317–1326. 2009.PubMed/NCBI View Article : Google Scholar
32	Cani PD, Amar J, Iglesias MA, Poggi M, Knauf C, Bastelica D, Neyrinck AM, Fava F, Tuohy KM, Chabo C, et al: Metabolic endotoxemia initiates obesity and insulin resistance. Diabetes. 56:1761–1772. 2007.PubMed/NCBI View Article : Google Scholar
33	Yang L, Francois F and Pei Z: Molecular pathways: Pathogenesis and clinical implications of microbiome alteration in esophagitis and Barrett esophagus. Clin Cancer Res. 18:2138–2144. 2012.PubMed/NCBI View Article : Google Scholar
34	Meng C, Bai C, Brown TD, Hood LE and Tian Q: Human gut microbiota and gastrointestinal cancer. Genomics Proteomics Bioinformatics. 16:33–49. 2018.PubMed/NCBI View Article : Google Scholar
35	Ladoire S, Martin F and Ghiringhelli F: Prognostic role of FOXP3+ regulatory T cells infiltrating human carcinomas: The paradox of colorectal cancer. Cancer Immunol Immunother. 60:909–918. 2011.PubMed/NCBI View Article : Google Scholar
36	Canani RB, Costanzo MD, Leone L, Pedata M, Meli R and Calignano A: Potential beneficial effects of butyrate in intestinal and extraintestinal diseases. World J Gastroenterol. 17:1519–1528. 2011.PubMed/NCBI View Article : Google Scholar
37	González-Sarrías A, Giménez-Bastida JA, Núñez-Sánchez MÁ, Larrosa M, García-Conesa MT, Tomás-Barberán FA and Espín JC: Phase-II metabolism limits the antiproliferative activity of urolithins in human colon cancer cells. Eur J Nutr. 53:853–864. 2014.PubMed/NCBI View Article : Google Scholar
38	Jinushi M, Nakazaki Y, Carrasco DR, Draganov D, Souders N, Johnson M, Mihm MC and Dranoff G: Milk fat globule EGF-8 promotes melanoma progression through coordinated Akt and twist signaling in the tumor microenvironment. Cancer Res. 68:8889–8898. 2008.PubMed/NCBI View Article : Google Scholar
39	Kong JC, Guerra GR, Pham T, Mitchell C, Lynch AC, Warrier SK, Ramsay RG and Heriot AG: Prognostic impact of tumor-infiltrating lymphocytes in primary and metastatic colorectal cancer: A Systematic review and meta-analysis. Dis Colon Rectum. 62:498–508. 2019.PubMed/NCBI View Article : Google Scholar

Journals